Clinical trial Recruiting at 1 site Observational Ages 18 and up

Understanding risk factors for cognitive problems in people with coronary heart disease

Official title: Association Between Modifiable Risk Factors and Cognitive Function in Patients With Coronary Heart Disease

Run by Beijing Anzhen Hospital · NCT07657624 · Data updated 2026-11-12

In people with coronary heart disease, this study tests how metabolic factors and imaging features relate to cognitive impairment.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment2352 (estimated)
SponsorBeijing Anzhen Hospital
Academic / other
Locations1 site (Beijing, China)
StatusRecruiting
StartedJune 30, 2025
Main results expectedMay 1, 2031
Study endsMay 1, 2031
Registry record updatedJuly 15, 2026
Trial IDNCT07657624 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with confirmed coronary heart disease who can complete neuropsychological testing and metabolic/imaging assessments.

Probably not a fit

Patients not experiencing cognitive impairment or those unable to complete imaging or neuropsychological testing may have limited direct benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational study enrolling about 2,352 adults with coronary heart disease at Beijing Anzhen Hospital. Participants undergo comprehensive cognitive testing, metabolic labs, and multimodal imaging (CCTA, cardiac MRI) plus sleep, frailty, and psychological assessments. The main goal is to identify risk factors associated with cognitive impairment and to explore possible mechanisms linking heart disease to brain function. Findings may help with early identification and personalized approaches to prevent or mitigate cognitive decline in CHD patients.

Why it matters

Potential benefit: If successful, the study could improve early detection of cognitive impairment in CHD patients and inform personalized strategies to reduce risk.

How similar studies have gone: Prior research in cardiovascular and metabolic health has linked cognitive changes to metabolic and imaging markers, but large-scale prospective data in CHD populations are less common, making this relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 18 years
2. Diagnosis of coronary heart disease (meeting at least one of the following):

   * Coronary angiography or coronary CTA showing ≥50% stenosis in ≥1 major coronary artery;
   * Established diagnosis of coronary heart disease with prior medical, interventional, or surgical treatment;
   * Objective evidence of myocardial ischemia or typical clinical symptoms
3. Completion of standardized neuropsychological assessment during hospitalization
4. Completion of metabolic marker evaluation (fasting glucose, insulin, HbA1c, etc.) and agreement to undergo relevant imaging and functional assessments
5. Provision of signed written informed consent

Exclusion Criteria:

1. Previously diagnosed dementia.
2. History of stroke, cerebral hemorrhage, or other central nervous system diseases known to cause cognitive impairment.
3. Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).
4. Pregnancy or breastfeeding.

Where it's running

  • Beijing Anzhen Hospital
    Beijing, China, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.